Home > Insider Trading > Filing (0000939767-19-000141)

Filing Details

Accession Number:: 0000939767-19-000141
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-06-19 21:30:12
Reporting Period:: 2019-06-17

Accepted Time:: 2019-06-19 21:30:12
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
939767	Exelixis Inc.	EXEL	Services-Commercial Physical & Biological Research (8731)	043257395

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1387306	Peter Lamb	C/O Exelixis, Inc. 1851 Harbor Bay Parkway Alameda CA 94502	Evp, Scientific Strategy & Cso	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-06-17	95,404	$5.56	212,601	No	4	M	Direct
Common Stock	Acquisiton	2019-06-17	4,596	$1.70	217,197	No	4	M	Direct
Common Stock	Disposition	2019-06-17	100,000	$20.49	117,197	No	4	S	Direct
Common Stock	Acquisiton	2019-06-18	75,404	$1.70	192,601	No	4	M	Direct
Common Stock	Acquisiton	2019-06-18	24,596	$5.51	217,197	No	4	M	Direct
Common Stock	Disposition	2019-06-18	100,000	$20.67	117,197	No	4	S	Direct
Common Stock	Acquisiton	2019-06-19	17,404	$5.51	134,601	No	4	M	Direct
Common Stock	Disposition	2019-06-17	17,404	$20.76	117,197	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option (right to buy)	Acquisiton	2019-06-17	95,404	$0.00	95,404	$5.56
Common Stock	Option (right to buy)	Acquisiton	2019-06-17	4,596	$0.00	4,596	$1.70
Common Stock	Option (right to buy)	Acquisiton	2019-06-18	75,404	$0.00	75,404	$1.70
Common Stock	Option (right to buy)	Acquisiton	2019-06-18	24,596	$0.00	24,596	$5.51
Common Stock	Option (right to buy)	Acquisiton	2019-06-19	17,404	$0.00	17,404	$5.51

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2013-09-21	2019-09-20	No	4	M	Direct
395,404	2015-07-20	2021-09-18	No	4	M	Direct
320,000	2015-07-20	2021-09-18	No	4	M	Direct
17,404	2015-07-20	2020-09-17	No	4	M	Direct
0	2015-07-20	2020-09-17	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	17,105	Indirect	By 401(k)

Footnotes

Includes 49,374 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2019.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.29 to $20.69. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.42 to $20.87. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.59 to $20.91. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 5 to this Form 4.
Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of June 17, 2019.
The option, representing the right to purchase a total of 123,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016.
The option, representing the right to purchase a total of 400,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.
On September 18, 2013, the Reporting Person was granted a performance-based stock option to purchase 84,000 shares of common stock under the Exelixis, Inc. 2011 Equity Incentive Plan. Vesting of the option is tied to performance goals set by the Compensation Committee ("Committee") as follows: (i) 50% of the option will vest if the Committee determines that top-line efficacy data received from the METEOR Phase 3 clinical trial of cabozantinib in metastatic renal cell carcinoma met its primary endpoint at a specified level, which the Committee determined had been achieved on July 20, 2015, resulting in the vesting of 50% of the option; and (ii) 50% of the option will vest if the Committee confirms the approval of cabozantinib by the U.S. Food and Drug Administration or European Medicines Agency for the treatment of metastatic castration-resistant prostate cancer, which the Committee determined could not be achieved on December 10, 2014, resulting in the forfeiture of 50% of the option.